Hiqa requires additional powers to regulate corporate nursing home companies
The Health Information and Quality Authority (Hiqa) would require additional powers to regulate parent companies of nursing homes, the Health Committee has been told.
The committee also heard that more than 15 per cent of the country's nursing homes are currently under some form of restrictive condition by Hiqa.
Advertisement
It comes after RTÉ Investigates examined standards of care at two nursing homes operated by Emeis Ireland, formerly known as Orpea.
The programme highlighted serious issues at two centres, The Residence Portlaoise and Beneavin Manor in Glasnevin, Dublin, which have been acknowledged as 'wholly unjustifiable' by Emeis Ireland.
Hiqa, which is responsible for inspecting nursing homes, said it had notified gardai about its concerns arising from the programme.
It also issued an official warning of cancellation of registration to the providers of the two nursing homes should they fail to implement significant improvements in the centres.
Advertisement
Hiqa chief executive Angela Fitzgerald told the Health Committee on Wednesday that the behaviour in the programme constituted a breach of 'basic human rights which can never be condoned'.
She said the inspection agency was 'really sorry to the families directly impacted and the wider community'.
A general view of Beneavin Manor nursing home in Dublin, Ireland (Niall Carson/PA)
An interim report on Tuesday evening revealed that there had been 198 allegations of abuse to a resident at Beneavin Manor from January 1st, 2022 to June 5th, 2025, with 40 such allegations at The Residence Portlaoise between December 14th, 2023 and June 6th, 2025.
Hiqa said it had also sought immediate assurances on the other 23 homes that Emeis Ireland owns, adding that it is clear it has significant work to do.
Advertisement
At committee, Sinn Féin health spokesman David Cullinane said what was shown in the programme was 'cost-cutting by a corporate body leading to neglect of residents' and 'substandard' care.
Asked if Hiqa had any powers to provide financial penalties against that corporate entity, Ms Fitzgerald said the authority that was not provided for under its legal framework.
Ms Fitzgerald said the authority has power to regulate individual providers but said it does not 'currently have any powers' in terms of requiring large corporate entities overseeing several providers to take action.
She said it was 'important that we have additional powers' for circumstances where it needs to act with such corporate entities.
Advertisement
She told the committee that there had been a shift towards large corporate entities in the nursing home space and said: 'We don't currently have powers to direct or require them to do anything – we work on the basis of cooperation.'
Ms Fitzgerald added: 'I do want to put on record today that the vast majority of those corporate entities as well as individual providers cooperate and work with us – but regulation is there to provide both action and a deterrent.
'And I think it is important that when there's a changing landscape, that we pause and look at whether we need additional regulatory powers to deal with circumstances such as this.'
Responding to a follow-up question from committee chairman and Social Democrat TD Padraig Rice, Deputy Chief Inspector Susan Cliffe said the approach taken by the authority begins with engaging with the provider and escalating through a process that includes advisories, cautions, and additional restrictive conditions on its operations.
Advertisement
She added that it ends with cancellation of service or forced closure as a 'nuclear option'.
Pressed on what additional measure could be taken against companies following cancellation that would prevent them from opening a different nursing home, Ms Cliffe said: 'I think we have the powers at the moment to regulate each individual nursing home, vis a vis the company that runs that nursing home.
'What we're talking about at a higher level is, if you would have the powers to go above that to the company that owns all of these companies, that's what doesn't currently exist.'
Ms Cliffe said the minister has discussed that potential with the authority.
Hiqa also told the committee that 95 of the country's 548 nursing homes are under 'additional restrictive conditions', 53 of which are HSE operated or funded.
The RTÉ Investigates documentary highlighted vulnerable people being left unsupervised, large amounts of residents congregated together being supervised by one member of staff, and requests for the use of toilets being unanswered for lengthy periods of time.
It also showed some staff not using proper hoisting equipment and shortages in necessary items like incontinence pads.
Mr Rice, the chairman of the committee, said the programme was 'very difficult and disturbing viewing'.
Emeis Ireland issued an apology to to all residents and their families for 'the suffering and distress experienced as a result of failures identified in the care provided'.
It said it recognised and deeply regrets the 'breach of trust' and 'any failure to uphold the dignity of some residents at all times'.
Emeis Ireland said it has commenced a comprehensive review across both nursing homes.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
4 hours ago
- The Independent
FDA approves the world's only twice-a-year shot to prevent HIV
The U.S. has approved the world's only twice-a-year shot to prevent HIV, maker Gilead Sciences announced Wednesday. It's the first step in an anticipated global rollout that could protect millions – although it's unclear how many in the U.S. and abroad will get access to the powerful new option. While a vaccine to prevent HIV still is needed, some experts say the shot — a drug called lenacapvir — could be the next best thing. It nearly eliminated new infections in two groundbreaking studies of people at high risk, better than daily preventive pills they can forget to take. 'This really has the possibility of ending HIV transmission,' said Greg Millett, public policy director at amfAR, The Foundation for AIDS Research. Condoms help guard against HIV infection if used properly but what's called PrEP — regularly using preventive medicines such as the daily pills or a different shot given every two months — is increasingly important. Lenacapavir's six-month protection makes it the longest-lasting type, an option that could attract people wary of more frequent doctor visits or stigma from daily pills. But upheaval in U.S. healthcare — including cuts to public health agencies and Medicaid — and slashing of American foreign aid to fight HIV are clouding the prospects. Millett said "gaping holes in the system" in the U.S. and globally "are going to make it difficult for us to make sure we not only get lenacapavir into people's bodies but make sure they come back' even as little as twice a year. Gilead's drug already is sold to treat HIV under the brand name Sunlenca. The prevention dose will be sold under a different name, Yeztugo. It's given as two injections under the skin of the abdomen, leaving a small 'depot' of medication to slowly absorb into the body. Gilead didn't immediately announce its price. The drug only prevents HIV transmission – it doesn't block other sexually transmitted diseases. Global efforts at ending the HIV pandemic by 2030 have stalled. There still are more than 30,000 new infections in the U.S. each year and about 1.3 million worldwide. Only about 400,000 Americans already use some form of PrEP, a fraction of those estimated to benefit. A recent study found states with high use of PrEP saw a decrease in HIV infections, while rates continued rising elsewhere. About half of new infections are in women, who often need protection they can use without a partner's knowledge or consent. One rigorous study in South Africa and Uganda compared more than 5,300 sexually active young women and teen girls given twice-yearly lenacapavir or the daily pills. There were no HIV infections in those receiving the shot while about 2% in the comparison group caught HIV from infected sex partners. A second study found the twice-yearly shot nearly as effective in gay men and gender-nonconforming people in the U.S. and in several other countries hard-hit by HIV. Ian Haddock of Houston had tried PrEP off and on since 2015 but he jumped at the chance to participate in the lenacapavir study and continues with the twice-yearly shots as part of the research follow-up. 'Now I forget that I'm on PrEP because I don't have to carry around a pill bottle,' said Haddock, who leads the Normal Anomaly Initiative, a nonprofit serving Black LGBTQ+ communities. ' Men, women, gay, straight – it really just kinds of expands the opportunity for prevention,' he added. Just remembering a clinic visit every six months 'is a powerful tool versus constantly having to talk about, like, condoms, constantly making sure you're taking your pill every day.' 'Everyone in every country who's at risk of HIV needs access to PrEP,' added Dr. Gordon Crofoot of Houston, who helped lead the study in men. 'We need to get easier access to PrEP that's highly effective like this is.' ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
The Independent
5 hours ago
- The Independent
What to know about the COVID variant causing 'razor blade' sore throats
The COVID-19 variant that may be driving a recent rise in cases in some parts of the world has earned a new nickname: 'razor blade throat' COVID. That's because the variant — NB.1.8.1. or 'Nimbus' — may cause painful sore throats. The symptom has been identified by doctors in the United Kingdom, India and elsewhere, according to media outlets in those countries. Other COVID-19 symptoms of any variant include fever, chills, cough, shortness of breath or loss of taste or smell. Experts say there isn't major cause for concern with the Nimbus variant, but here 's what else you need to know about it. Here's where the variant causing 'razor blade throat' spreading The rise in cases late last month is primarily in eastern Mediterranean, Southeast Asia and western Pacific regions, the World Health Organization said May 28. The new variant had reached nearly 11% of sequenced samples reported globally in mid-May. Airport screening in the United States detected the new variant in travelers arriving from those regions to destinations in California, Washington state, Virginia and New York. You aren't likely to get sicker from this variant than others Not so far, anyway. The WHO said some western Pacific countries have reported increases in COVID cases and hospitalizations, but there's nothing so far to suggest that the disease associated with the new variant is more severe compared to other variants. COVID-19 vaccines are effective against the Nimbus variant Yes. The WHO has designated Nimbus as a 'variant under monitoring' and considers the public health risk low at the global level. Current vaccines are expected to remain effective. Health Secretary Robert F. Kennedy Jr. announced last month that COVID-19 shots are no longer recommended for healthy children and pregnant women — a move immediately questioned by public health experts. ___ AP Health Writer Carla Johnson contributed to this story. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Medical News Today
5 hours ago
- Medical News Today
Postmenopausal breast cancer: Risk, symptoms, and more
Link MHT and breast cancer Other risk factors Contacting a doctor FAQ Postmenopausal breast cancer occurs at higher rates due to cumulative hormone exposure and age-related cellular changes that increase cancer risk. Breast cancer develops when cells in breast tissue begin to grow and divide uncontrollably, forming tumors that can spread to other parts of the body. The risk of breast cancer increases significantly with age, particularly after menopause, when hormonal and cellular changes create an environment more conducive to cancer development. This article explores postmenopausal breast cancer risk, symptoms to watch for, and risk reduction strategies following menopause. Curly_photo/Getty Images Yes, the risk of breast cancer can increase after menopause. Statistics show that the likelihood of developing breast cancer rises with age, with about 1 in 8 women developing the disease during their lifetime, and the majority of these cases occurring after menopause. In those ages 20 to 24, there are 1.5 breast cancer cases per 100,000. This figure jumps to more than 421 cases in those ages 75 to 79. More than 9 in 10 new female breast cancer cases occur in those ages 40 or over. This age-related increase means that postmenopausal people may benefit from regular screening. The relationship between breast cancer and menopause centers on the length of hormone exposure. During reproductive years, the body produces estrogen and progesterone every month as part of the menstrual cycle. These hormones signal breast cells to grow and divide, a process that is entirely natural. However, each time cells divide, there is a slight chance for mistakes to occur in the DNA. Over many years, these mistakes can accumulate and potentially lead to cancer development. While menopause itself does not directly cause cancer, breast cancer risk naturally increases with age. Those who experience menopause later in life, after age 55, have a higher risk of breast cancer because their bodies were exposed to reproductive hormones for longer periods. Menopausal hormone therapy (MHT) is another consideration. Many people use MHT during perimenopause to manage symptoms such as hot flashes, but some types of MHT increase breast cancer risk. The risk appears to be higher with combined estrogen and progesterone treatment compared to estrogen alone. MHT can increase breast cancer risk, but the level of risk depends on the specific type of HRT used. Combination MHT, which contains both estrogen and progesterone, poses a higher risk than estrogen-only therapy. Estrogen-only MHT is typically used by those who have had hysterectomies. It does not appear to be linked to an increased breast cancer risk, making it a safer option for appropriate candidates. MHT may increase the initial risk of developing breast cancer and make it more likely that cancer will be detected at advanced stages. According to this occurs partly because combination MHT increases breast density, making mammograms less effective at spotting early cancers. The risk appears greater with daily progesterone use compared to less frequent dosing schedules. The dose and duration of MHT also play a significant role in breast cancer risk. Higher doses carry a greater risk than lower doses, and this increased risk can persist for more than 10 years after treatment stops. These findings apply to both synthetic hormones and bioidentical products, despite marketing claims that natural hormones are safer. Anyone considering MHT should discuss their risk factors with healthcare professionals to weigh the benefits of symptom relief against potential cancer risks. Reproductive history : Never having children or having a first child after age 30 increases the risk. Pregnancy lowers breast cell exposure to circulating estrogen. The more children a person has, the greater the protection against breast cancer. : Never having children or having a first child after age 30 increases the risk. Pregnancy lowers breast cell exposure to circulating estrogen. The more children a person has, the greater the protection against breast cancer. Lifestyle factors : A lack of physical activity and excessive alcohol consumption can contribute to increased risk. Smoking, particularly if started at a young age, also elevates breast cancer risk. : A lack of physical activity and excessive alcohol consumption can contribute to increased risk. Smoking, particularly if started at a young age, also elevates breast cancer risk. Medical factors : Previous breast biopsies showing atypical cells, family history of breast or ovarian cancer, and genetic mutations such as BRCA1 or BRCA2 significantly increase risk. Radiation exposure to the chest area, particularly during adolescence, also contributes to elevated risk. : Previous breast biopsies showing atypical cells, family history of breast or ovarian cancer, and genetic mutations such as BRCA1 or BRCA2 significantly increase risk. Radiation exposure to the chest area, particularly during adolescence, also contributes to elevated risk. Dense breast tissue: Dense breast tissue has a higher risk of developing breast cancer and may require additional screening methods beyond standard mammography. Maintain a moderate weight : Working toward and maintaining a moderate weight through balanced nutrition and regular physical activity significantly reduces risk. : Working toward and maintaining a moderate weight through balanced nutrition and regular physical activity significantly reduces risk. Exercise regularly : Aim for at least 150 minutes of moderate-intensity aerobic activity per week, plus two sessions of strength training exercises each week. : Aim for at least 150 minutes of moderate-intensity aerobic activity per week, plus two sessions of strength training exercises each week. Limit alcohol consumption : Restrict alcohol intake to no more than one drink per day, as alcohol consumption is linked to increased breast cancer risk at any level of intake. : Restrict alcohol intake to no more than one drink per day, as alcohol consumption is linked to increased breast cancer risk at any level of intake. Follow screening guidelines : Adhere to the recommended mammography schedules, typically once or twice a year, depending on age and risk factors. People with a higher risk may need additional screening methods. : Adhere to the recommended mammography schedules, typically once or twice a year, depending on age and risk factors. People with a higher risk may need additional screening methods. Consider preventive medications: For high risk individuals, medications like tamoxifen or raloxifene may reduce breast cancer risk by around 40% . These decisions require careful discussion with oncologists or breast specialists. A person should contact a doctor if they notice any symptoms of breast cancer. Postmenopausal individuals should be particularly vigilant because they no longer experience monthly breast changes related to menstrual cycles, making new abnormalities more significant. Any persistent change lasting more than 2 weeks warrants medical evaluation. Although regular self-examinations are not a replacement for professional screening, they can help people become familiar with their normal breast tissue and detect changes early. Invasive ductal carcinoma (IDC) accounts for about 80% of breast cancer cases and breast cancer mainly develops in those around the age of 62. Generally, yes. After menopause, the body produces much less estrogen and progesterone, the hormones that many breast cancers depend on to grow and spread. With lower hormone levels after menopause, these cancers receive weaker growth signals and tend to develop more slowly. This hormonal change creates a less favorable environment for cancer growth compared to the higher hormone levels present during reproductive years. Yes, postmenopausal breast cancer is typically less aggressive. Many breast cancers in older individuals are 'hormone-receptor-positive,' meaning they have receptors that allow hormones to fuel their growth. These hormone-positive cancers respond well to treatments that block hormones or prevent the body from making them, essentially cutting off the cancer's fuel supply. Postmenopausal breast cancer risk increases significantly with age. The relationship between menopause and breast cancer stems from cumulative hormonal exposure and age-related cellular changes. Risk factors include MHT, excess weight, family history, and lifestyle factors. People can reduce their risk by maintaining a moderate weight, engaging in regular exercise, limiting alcohol consumption, and following screening guidelines. While postmenopausal breast cancers are often hormone receptor-positive and slower-growing, early detection remains crucial for optimal outcomes. Symptoms may be subtle but include new lumps, breast changes, and nipple abnormalities. Breast Cancer Menopause Cancer / Oncology
